AOD-9604 New York telehealth access may let eligible adults request a provider review, but it does not guarantee that treatment is available or appropriate for them. AOD-9604 is an investigational peptide with limited evidence for weight loss and is not FDA-approved for this use.

Ready to find out if you qualify? Start Free Assessment — No payment required

What AOD-9604 is—and what it is proposed to do

AOD-9604 is a synthetic peptide fragment derived from a portion of human growth hormone. It has been studied for possible effects on fat metabolism. The proposed mechanism is that it may influence fat breakdown without producing all the growth-promoting effects associated with intact growth hormone. That proposed distinction does not establish safety or effectiveness in people seeking weight management.

A peptide’s proposed biological activity is not the same as proof of a clinically meaningful benefit. AOD-9604 is not an FDA-approved weight-loss medication, and claims made in wellness marketing should not be treated as established medical facts. Research findings from laboratory or animal studies cannot establish that a product will cause weight loss in humans.

For an overview of the product, its limitations, and provider review, see EdenRx’s AOD-9604 program information. This New York page focuses on access and decision-making rather than implying that the peptide is a standard or proven treatment.

AOD-9604 New York availability: what telehealth does and does not mean

Telehealth can make it possible to request a clinical assessment without visiting a local clinic. EdenRx serves patients in Florida and New York; online access is not a claim that EdenRx has a physical clinic in every New York community. State-specific licensing and clinical rules apply, and services are subject to provider availability.

Submitting an assessment is a request for review—not approval, a diagnosis, or a promise that AOD-9604 can be prescribed or supplied. A provider may decide that the evidence is insufficient for the patient’s goals, that risks or medical history make a particular option unsuitable, or that another approach should be considered. Availability may also depend on applicable law, clinical judgment, and the specific product or service being offered.

People comparing broader care options can review online weight loss services in New York, program information, and pricing details. These pages can help clarify the service pathway; they do not replace individualized medical advice.

What the human evidence can—and cannot—tell you

Evidence for AOD-9604 as a weight-loss treatment is limited and does not establish it as an effective, FDA-approved therapy. Early research and clinical investigations have explored the peptide, but the existence of a study or a biological hypothesis is not enough to support claims of reliable weight loss, long-term benefit, or prevention of weight-related disease. Study design, size, duration, and relevance to current products all matter when judging evidence.

The FDA’s information about compounding explains that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness, or quality before marketing in the way FDA-approved drugs are. A compounded preparation is not the same as an FDA-approved product and should not be presented as a generic or equivalent version of one. Whether a specific preparation can lawfully be compounded and prescribed depends on applicable federal and state requirements and the clinical circumstances.

For context, FDA-approved prescription options for chronic weight management have their own clinical evidence, indications, contraindications, and prescribing information. They are not interchangeable with AOD-9604. If comparing established medication pathways, see semaglutide versus tirzepatide and tirzepatide in New York. A provider can discuss whether any option is appropriate; comparison pages cannot determine eligibility.

Safety, uncertainty, and questions to raise

AOD-9604’s safety profile for weight management is not established to the same standard as an FDA-approved medicine with an approved indication and prescribing information. Limited evidence means clinicians and patients may not have dependable answers about uncommon adverse effects, long-term effects, interactions, or which patients face greater risks. Do not assume that a peptide is safe because it is described as “natural,” is sold online, or is administered by injection.

Before considering any peptide or weight-management treatment, tell the reviewing provider about prescription medicines, nonprescription drugs, supplements, allergies, past treatments, and relevant health conditions. If you are pregnant, trying to become pregnant, or breastfeeding, discuss this before pursuing treatment. Seek urgent medical care for severe or rapidly worsening symptoms after any medication or injection.

Use this checklist during a consultation:

| Ask the provider | Why it matters | | --- | --- | | Is this product FDA-approved for the proposed use? | Approval status and evidence differ across products and indications. | | What human evidence supports this specific option? | Proposed mechanisms and marketing claims do not establish clinical benefit. | | What is known—and not known—about risks and interactions? | Safety information may be incomplete, especially for investigational products. | | If compounding is involved, what is the legal and clinical basis? | Compounded drugs are not FDA-approved and are subject to specific requirements. | | What alternatives fit my goals and medical history? | A clinician can consider approved treatments and non-drug support where appropriate. |

Why Provider Review Matters

A responsible review considers more than a location or a requested product. A licensed provider should assess health history, current medications, treatment goals, potential contraindications, and the quality of evidence for the option being discussed. They may request additional information, recommend a different plan, or decide that no medication is appropriate.

For New York patients, telehealth care must be provided in accordance with applicable state requirements. An online assessment is a starting point, not an automatic prescription. The provider-patient relationship and any treatment decision depend on an appropriate clinical evaluation and provider judgment.

EdenRx’s assessment process is intended to help determine whether a next step may be appropriate. Review the AOD-9604 program hub for product-specific information, and ask the care team to clarify what is offered, what is investigational, and what alternatives may be available. No result is guaranteed; results vary.

Want a clinician to review your goals and health history? Start the free assessment to request an evaluation. No payment is required to begin.

Evidence and authoritative sources

The following sources are useful for understanding the limits of evidence and the rules around drug approval and compounding:

• The U.S. Food and Drug Administration’s Compounding and the FDA: Questions and Answers explains that compounded drugs are not FDA-approved and describes important distinctions from approved drugs.
• The FDA’s Human Drug Compounding resources provide information on federal oversight, compounding conditions, and safety concerns.
• PubMed, maintained by the U.S. National Library of Medicine at the NIH, provides a searchable record of published medical research. Searching PubMed for AOD-9604 lets readers examine the available literature and assess its scope; a search result alone is not proof of effectiveness.

These sources do not establish AOD-9604 as an FDA-approved weight-loss treatment. Evidence and regulatory status should be checked directly with authoritative sources and a qualified clinician, particularly because products and rules may change.

Built from Eden Med Spa — real patients, real treatments.

Frequently Asked Questions

Can I get AOD-9604 in New York through telehealth?

You may request a telehealth assessment if services are available to you, but access does not guarantee that AOD-9604 is offered, legally available for your situation, clinically appropriate, or prescribed. A licensed provider must review your case.

Is AOD-9604 FDA-approved for weight loss?

No. AOD-9604 is not FDA-approved for weight loss. Do not confuse a proposed mechanism, research interest, or a compounded preparation with FDA approval.

Does a free assessment mean I will receive a prescription?

No. The assessment begins a review and does not guarantee eligibility, treatment, or a prescription. A provider may recommend another approach or determine that medication is not appropriate.

Is compounded AOD-9604 the same as an FDA-approved weight-loss medication?

No. Compounded drugs are not FDA-approved, and they are not the same as or equivalent to FDA-approved products. Compounding is subject to legal and clinical requirements; ask the provider what applies to the specific product being discussed.

How does AOD-9604 compare with semaglutide or tirzepatide?

They are different substances with different evidence, regulatory status, and clinical considerations. AOD-9604 is not FDA-approved for weight loss. Semaglutide and tirzepatide products have specific FDA-approved indications and prescribing information, but not every formulation or use is approved. A clinician can discuss options based on your circumstances. See semaglutide versus tirzepatide for general context.

What should I ask before considering a peptide?

Ask whether it is FDA-approved for the intended use, what human evidence supports it, what risks and uncertainties are known, whether it may interact with your medicines, and what alternatives are available. Share your complete medical and medication history with the provider.

The bottom line

AOD-9604 New York searches often reflect interest in convenient access, but telehealth does not remove the need for evidence-based judgment or guarantee eligibility. AOD-9604 is not FDA-approved for weight loss, and important questions about effectiveness and safety remain. If you are considering care, use a provider review to discuss your goals, medical history, evidence, and possible alternatives—not to assume a particular peptide is suitable.

Start a free assessment to request a provider review. No payment is required to begin; treatment is not guaranteed, and results vary.